2020. An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s73. DOI:https://doi.org/10.25251/skin.4.supp.73.